Concerns Rise Over Safety of Weight-Loss Drugs in Pregnancy

Recent reports highlight unplanned pregnancies and potential risks to babies from popular weight-loss medications.

British scientists warn that the weight-loss drug semaglutide, used in brands like Ozempic and Wegovy, may pose risks to developing babies when used during pregnancy.
Women using semaglutide have reported unexpected pregnancies, raising concerns about its safety and prompting calls for caution before conception.
Experts emphasize the lack of comprehensive data on the drug's safety during pregnancy, with animal studies suggesting potential reproductive toxicity.
Healthcare professionals advise women to discontinue use of semaglutide at least two months before attempting conception to minimize risks.
Ongoing research and data collection efforts are crucial to understanding the full impact of weight-loss drugs on fertility and pregnancy outcomes.